Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 20/20 | 0.65 |
| ▸ | CHRM2 | P08172 | 7/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 6/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL2191553 | 0.99 | CHRM3 (0.64) | CHRM3CHRM2CHRM1 | |
| Bromide SCHEMBL1428260 | 0.99 | CHRM3 (0.64) | CHRM3CHRM2CHRM1 | |
| SCHEMBL10147608 | 0.91 | CHRM3 (0.76) | CHRM3CHRM2CHRM1 | |
| Bromide SCHEMBL1041421 | 0.90 | CHRM3 (0.75) | CHRM3CHRM2CHRM1 | |
| SCHEMBL10147664 | 0.90 | CHRM3 (0.73) | CHRM3CHRM2CHRM1 | |
| Bromide SCHEMBL1040519 | 0.89 | CHRM3 (0.72) | CHRM3CHRM2CHRM1 | |
| SCHEMBL12415497 | 0.87 | CHRM3 (0.69) | CHRM3CHRM2CHRM1 | |
| SCHEMBL12415512 | 0.86 | CHRM3 (0.67) | CHRM3CHRM2CHRM1 | |
| Bromide SCHEMBL2188937 | 0.86 | CHRM3 (0.66) | CHRM3CHRM2CHRM1 | |
| Bromide SCHEMBL1428835 | 0.86 | CHRM3 (0.66) | CHRM3CHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130030001-A1 | QUINUCLIDINE DERIVATIVES AS MUSCARINIC M3 RECEPTOR ANTAGONISTS | PULMAGEN THERAPEUTICS (SYNERGY) LIMITED (GB) | 2013-01-31 | — | — | US | disclosed |
| US-8329729-B2 | Quinuclidine derivatives as muscarinic M3 receptor antagonists | ASTRAZENECA AB (SE) | 2012-12-11 | — | — | US | disclosed |
| US-20110172237-A1 | QUINUCLIDINE DERIVATIVES AS MUSCARINIC M3 RECEPTOR ANTAGONISTS | ASTRAZENECA UK LIMITED (GB) | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172237-A1 | QUINUCLIDINE DERIVATIVES AS MUSCARINIC M3 RECEPTOR ANTAGONISTS | CHRM3, CHRM2, CHRM1 | CHRM3 1/4885CHRM2 2/4885CHRM1 3/4885 |
| US-20130030001-A1 | QUINUCLIDINE DERIVATIVES AS MUSCARINIC M3 RECEPTOR ANTAGONISTS | CHRM3, CHRM2, CHRM5 | CHRM3 1/4885CHRM2 2/4885CHRM1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.